MX385762B - Métodos para el control transcripcional objetivo en regiones del super mejorador. - Google Patents
Métodos para el control transcripcional objetivo en regiones del super mejorador.Info
- Publication number
- MX385762B MX385762B MX2017005861A MX2017005861A MX385762B MX 385762 B MX385762 B MX 385762B MX 2017005861 A MX2017005861 A MX 2017005861A MX 2017005861 A MX2017005861 A MX 2017005861A MX 385762 B MX385762 B MX 385762B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- transcriptional control
- super
- enhancer regions
- super enhancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077042P | 2014-11-07 | 2014-11-07 | |
| US201562150110P | 2015-04-20 | 2015-04-20 | |
| PCT/US2015/059566 WO2016073913A1 (en) | 2014-11-07 | 2015-11-06 | Methods to target transcriptional control at super-enhancer regions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017005861A MX2017005861A (es) | 2017-06-26 |
| MX385762B true MX385762B (es) | 2025-03-18 |
Family
ID=55909897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005861A MX385762B (es) | 2014-11-07 | 2015-11-06 | Métodos para el control transcripcional objetivo en regiones del super mejorador. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20180280407A1 (enExample) |
| EP (1) | EP3215135B1 (enExample) |
| JP (1) | JP6689841B2 (enExample) |
| KR (1) | KR20170092543A (enExample) |
| CN (1) | CN107205959B (enExample) |
| AU (1) | AU2015342813B2 (enExample) |
| BR (1) | BR112017009552A8 (enExample) |
| CA (1) | CA2965690A1 (enExample) |
| IL (1) | IL251816B (enExample) |
| MX (1) | MX385762B (enExample) |
| RU (1) | RU2737508C2 (enExample) |
| WO (1) | WO2016073913A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3611506B1 (en) | 2015-04-20 | 2021-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| ES2921350T3 (es) | 2015-05-18 | 2022-08-24 | Sumitomo Pharma Oncology Inc | Profármacos de alvocidib que tienen biodisponibilidad aumentada |
| BR112018002427A8 (pt) | 2015-08-03 | 2022-10-18 | Tolero Pharmaceuticals Inc | Uso de alvocidib e de azacitidina ou decitabina para tratar câncer e kit e composição farmacêutica contendo as ditas substâncias |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| JP6619519B2 (ja) | 2016-12-19 | 2019-12-11 | トレロ ファーマシューティカルズ， インコーポレイテッド | プロファイリングペプチドおよび感受性プロファイリングのための方法 |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| WO2019113260A1 (en) * | 2017-12-05 | 2019-06-13 | The Regents Of The University Of Colorado A Body Corporate | Genomic targets of histone deacetylase inhibitors (hdaci) and methods of use thereof |
| US20200405809A1 (en) * | 2018-02-27 | 2020-12-31 | Pfizer Inc. | Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor |
| WO2020078924A1 (en) | 2018-10-15 | 2020-04-23 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Compounds for treatment of diseases and methods of screening therefor |
| JP2022511029A (ja) | 2018-12-04 | 2022-01-28 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形 |
| AU2020219368A1 (en) | 2019-02-08 | 2021-07-15 | Dewpoint Therapeutics, Inc. | Methods of characterizing condensate-associated characteristics of compounds and uses thereof |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| KR20220084047A (ko) | 2019-09-18 | 2022-06-21 | 듀포인트 테라퓨틱스, 인크. | 응축물 관련 특이성에 대한 스크리닝 방법 및 이의 용도 |
| EP4453261A1 (en) * | 2021-12-22 | 2024-10-30 | Cornell University | Prognostic/predictive epigenetic breast cancer signature |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030026069A (ko) * | 2001-09-24 | 2003-03-31 | 주식회사 엘지생명과학 | 티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물 |
| RU2438664C2 (ru) * | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
| EP2561867A1 (en) * | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
| EP3066101B1 (en) * | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| EP3206749B1 (en) * | 2014-10-14 | 2021-09-08 | The Regents of the University of California | The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation |
-
2015
- 2015-11-06 CN CN201580060262.XA patent/CN107205959B/zh not_active Expired - Fee Related
- 2015-11-06 JP JP2017523502A patent/JP6689841B2/ja active Active
- 2015-11-06 KR KR1020177013707A patent/KR20170092543A/ko not_active Ceased
- 2015-11-06 US US15/524,953 patent/US20180280407A1/en not_active Abandoned
- 2015-11-06 CA CA2965690A patent/CA2965690A1/en not_active Abandoned
- 2015-11-06 MX MX2017005861A patent/MX385762B/es unknown
- 2015-11-06 RU RU2017118833A patent/RU2737508C2/ru active
- 2015-11-06 BR BR112017009552A patent/BR112017009552A8/pt not_active Application Discontinuation
- 2015-11-06 EP EP15857385.7A patent/EP3215135B1/en active Active
- 2015-11-06 AU AU2015342813A patent/AU2015342813B2/en not_active Ceased
- 2015-11-06 WO PCT/US2015/059566 patent/WO2016073913A1/en not_active Ceased
-
2017
- 2017-04-20 IL IL251816A patent/IL251816B/en unknown
-
2019
- 2019-12-30 US US16/730,810 patent/US20200316084A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015342813B2 (en) | 2021-04-22 |
| EP3215135B1 (en) | 2020-05-13 |
| KR20170092543A (ko) | 2017-08-11 |
| RU2017118833A (ru) | 2018-12-10 |
| AU2015342813A1 (en) | 2017-05-18 |
| CN107205959A (zh) | 2017-09-26 |
| EP3215135A1 (en) | 2017-09-13 |
| JP6689841B2 (ja) | 2020-04-28 |
| RU2017118833A3 (enExample) | 2019-06-17 |
| RU2737508C2 (ru) | 2020-12-01 |
| BR112017009552A8 (pt) | 2022-10-18 |
| MX2017005861A (es) | 2017-06-26 |
| BR112017009552A2 (pt) | 2018-01-02 |
| JP2017533222A (ja) | 2017-11-09 |
| CN107205959B (zh) | 2021-02-12 |
| WO2016073913A1 (en) | 2016-05-12 |
| CA2965690A1 (en) | 2016-05-12 |
| IL251816B (en) | 2022-03-01 |
| US20200316084A1 (en) | 2020-10-08 |
| IL251816A0 (en) | 2017-06-29 |
| US20180280407A1 (en) | 2018-10-04 |
| EP3215135A4 (en) | 2018-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| MX391981B (es) | Derivados de benzooxazol como inmunomoduladores. | |
| MX389513B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| UY37205A (es) | Inhibidores de bromodominios | |
| CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| MX2018010993A (es) | Derivados de icariina e icaritina. | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| MX2018012230A (es) | Métodos para tratar enfermedades oculares. | |
| MX2017005064A (es) | Metodos para tratar afecciones oculares. | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| MX387726B (es) | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. | |
| MX2015009277A (es) | Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina. | |
| EA201891439A1 (ru) | Трициклические соединения и их композиции в качестве ингибиторов киназ | |
| BR112016017493A2 (pt) | Agentes terapêuticos direcionados |